Overview

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the progression-free survival of two treatment regimens for relapsed ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborator:
Aventis Pharmaceuticals
Treatments:
Carboplatin
Docetaxel